Biotechnology company Amgen on Wednesday provided a statement regarding the Phase 1 data of MariTide (maridebart cafraglutide, previously known as AMG 133), emphasizing that there is no observed link between MariTide administration and changes in bone mineral density.
The company reiterated that the Phase 1 study results show no bone safety concerns, maintaining confidence in MariTide's potential.
Amgen anticipates sharing the topline results from the Phase 2 study later in the year.
The company's investment in research and development has resulted in a robust pipeline that builds on it existing portfolio of medicines to treat cancer, heart disease, osteoporosis inflammatory diseases and rare diseases.
Insilico Medicine reports positive results from Phase I ISM5411 studies in Australia and China
Chime Biologics and Mabgeek completes Process Performance Qualification for MG-K10
argenx receives Japanese approval for VYVDURA in chronic inflammatory demyelinating polyneuropathy
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Vanda Pharmaceuticals receives Orphan Drug Designation from FDA for VGT-1849A
Hansa Biopharma reports positive Phase 2 imlifidase results
Gilead Sciences secures positive CHMP opinion for seladelpar in PBC treatment
GSK's Submission for Nucala (mepolizumab) in COPD accepted by US FDA
Evommune presents positive data from EVO756 first-in-human proof-of-concept trial
Rigel Pharmaceuticals' R289 granted US FDA Fast Track designation
Revelation Biosciences secures FDA acceptance for Gemini IND, Phase 1b CKD study set for 2025
Formosa Pharmaceuticals licenses eye drops for Switzerland and Liechtenstein